Abstract
Boehringer Ingelheim has granted Gilead Sciences exclusive worldwide rights for the research, development and commercialisation of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV, including the lead compound BI-224436, which has completed a Phase Ia dose escalation study in healthy volunteers. In return, Boehringer Ingelheim will receive an upfront payment, potential development, regulatory and commercial milestone payments as well as royalties. The licensed compounds are complementary to Gilead’s internal discovery programmes.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call